Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 1.00 |
| ▸ | VEGFA | P15692 | 8/20 | 0.80 |
| ▸ | FLT1 | P17948 | 8/20 | 0.80 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.80 |
| ▸ | TET3 | O43151 | 1/20 | 0.58 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.58 |
| ▸ | ASPH | Q12797 | 1/20 | 0.58 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.58 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.58 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.58 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.58 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287594 | 1.00 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL1921647 | 0.89 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL1921766 | 0.88 | EGLN1 (0.79) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL30239221 | 0.88 | EGLN1 (0.79) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL30287599 | 0.88 | EGLN1 (0.80) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL1921959 | 0.88 | EGLN1 (0.80) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL1921387 | 0.87 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30239178 | 0.87 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL1921999 | 0.87 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL1920683 | 0.86 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044005-B8 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2012-12-05 | — | — | EP | claimed |
| US-8323671-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
| EP-2044005-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2010-10-20 | — | — | EP | claimed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | claimed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| US-12629357-B2 | Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer | AKEBIA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250352527-A1 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | AKEBIA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025029611-A1 | THERAPIES FOR DISEASES OF COPPER METABOLISM | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2024-10-31 | — | — | US | disclosed |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885VEGFA 76/4885FLT1 90/4885 |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20250352527-A1 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | HIF1A, HIF1AN, EGLN3 | EGLN1 6/4885VEGFA 480/4885FLT1 240/4885 |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-12629357-B2 | Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer | HIF1A, HIF1AN, EGLN3 | EGLN1 9/4885VEGFA 77/4885FLT1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.